Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2011 1
2012 1
2013 1
2014 1
2015 1
2018 1
2019 3
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular ou …
BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials inv …
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Ruilope LM, et al. Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30. Am J Nephrol. 2019. PMID: 31665733 Free PMC article. Clinical Trial.
However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. PATIENTS AND METHODS: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of …
However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. PATIENTS AND METHODS: T …
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. METHODS: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease -(FIDELIO-DKD) trial aims to assess the efficacy and safety o …
However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. METHODS: The Finerenone …
Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge.
Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, Sköldunger A, Karlsson A, Anderson R, Belger M, Brück C, Espinosa R, Hlávka JP, Jutkowitz E, Lin PJ, Mendez ML, Mar J, Shewmaker P, Spackman E, Tafazzoli A, Tysinger B, Jönsson L; IPECAD modeling workshop 2020 participants. Handels RLH, et al. Alzheimers Dement. 2023 May;19(5):1800-1820. doi: 10.1002/alz.12811. Epub 2022 Oct 25. Alzheimers Dement. 2023. PMID: 36284403 Free PMC article.
High-Density, Long-Lasting, and Multi-region Electrophysiological Recordings Using Polymer Electrode Arrays.
Chung JE, Joo HR, Fan JL, Liu DF, Barnett AH, Chen S, Geaghan-Breiner C, Karlsson MP, Karlsson M, Lee KY, Liang H, Magland JF, Pebbles JA, Tooker AC, Greengard LF, Tolosa VM, Frank LM. Chung JE, et al. Neuron. 2019 Jan 2;101(1):21-31.e5. doi: 10.1016/j.neuron.2018.11.002. Epub 2018 Nov 27. Neuron. 2019. PMID: 30502044 Free PMC article.
Current methods to monitor neural activity, however, lack the necessary conjunction of anatomical spatial coverage, temporal resolution, and long-term stability to measure this distributed activity. Here we introduce a large-scale, multi-site, extracellular recording platf …
Current methods to monitor neural activity, however, lack the necessary conjunction of anatomical spatial coverage, temporal resolution, and …
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, Claire GK, Frank MJ, Muffly L, Shiraz P, Meyer E, Arai S, Brown JW, Johnston L, Lowsky R, Negrin RS, Rezvani AR, Weng WK, Latchford T, Sahaf B, Mackall CL, Miklos DB, Sidana S. Baird JH, et al. Blood Adv. 2021 Jan 12;5(1):143-155. doi: 10.1182/bloodadvances.2020002732. Blood Adv. 2021. PMID: 33570626 Free PMC article.
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious compl …
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed …
Lentigo maligna with spread onto oral mucosa.
Kroumpouzos G, Frank EW, Albertini JG, Krivo JM, Ramsey ML, Tyler WB, Cohen LM. Kroumpouzos G, et al. Arch Dermatol. 2002 Sep;138(9):1216-20. doi: 10.1001/archderm.138.9.1216. Arch Dermatol. 2002. PMID: 12224983
Spread of LM onto the conjunctiva has been reported. There have been no reports of LM extending onto oral mucosa. OBSERVATIONS: We report 4 cases of LM in white women with contiguous spread from perioral areas to oral mucosa. ...
Spread of LM onto the conjunctiva has been reported. There have been no reports of LM extending onto oral mucosa. OBSERVATIONS …
Clinical and Functional Outcomes of Documented Knee Dislocation Versus Multiligamentous Knee Injury: A Comparison of KD3 Injuries at Mean 6.5 Years Follow-up.
Hughes AJ, Li ZI, Garra S, Green JS, Chalem I, Triana J, Jazrawi LM, Medvecky MJ, Alaia MJ. Hughes AJ, et al. Am J Sports Med. 2024 Mar;52(4):961-967. doi: 10.1177/03635465241231032. Epub 2024 Feb 24. Am J Sports Med. 2024. PMID: 38400667
PURPOSE: To determine whether the knee dislocation-3 (KD3) injury pattern of MLKI with documented tibiofemoral dislocation represents a more severe injury than KD3 MLKI without documented dislocation, as manifested by poorer clinical outcomes at long-term follow-up. STUDY …
PURPOSE: To determine whether the knee dislocation-3 (KD3) injury pattern of MLKI with documented tibiofemoral dislocation represents a more …
Kinematic and kinetic interactions during normal and ACL-deficient gait: a longitudinal in vivo study.
Atarod M, Frank CB, Shrive NG. Atarod M, et al. Ann Biomed Eng. 2014 Mar;42(3):566-78. doi: 10.1007/s10439-013-0914-3. Epub 2013 Sep 18. Ann Biomed Eng. 2014. PMID: 24046151
These interactions change following ACL transection, in both short (4 weeks) and long (20 weeks) term. Ten skeletally mature sheep were used in control (N = 5) and experimental (N = 5) groups. ...PCL and PCL vs. LM/MM loads. These kinetic interaction patterns were c …
These interactions change following ACL transection, in both short (4 weeks) and long (20 weeks) term. Ten skeletally mature sheep we …
14 results